Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 19, 2026

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

View original at finance.yahoo.com
“lifted cash to $18.2B at year-end 2025 from $3.3B a year earlier.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AT&T legacy wireline revenue declined more than 20% in 2026

    60% confidence

  • Analyst consensus target price for Pfizer is $29.19

    60% confidence

  • Analyst target price for SoFi Technologies is $21.10

    60% confidence

  • Analyst target price for AT&T is $30.37

    60% confidence

  • AT&T's converged connectivity and growing free cash flow makes the dividend durable

    60% confidence

  • Pfizer faces a $1.5 billion revenue headwind in 2026 from loss of drug exclusivity and Most Favored Nation drug pricing pressure

    60% confidence

  • Equity markets are trading at elevated multiples in May 2026

    60% confidence

  • AT&T grew its cash position from $3.3 billion at year-end 2024 to $18.2 billion at year-end 2025

    60% confidence

  • SoFi Q1 2026 net income increased 134% year-over-year to $166.7 million

    60% confidence

  • SoFi Q1 2026 loan originations reached a record $12.18 billion, up 68% year-over-year

    60% confidence

  • Pfizer's non-COVID portfolio achieved 9% operational revenue growth

    60% confidence

  • AT&T Q1 2026 adjusted EPS grew 11.8% year-over-year to $0.57

    60% confidence

Data points we hold from this source

AT&T Inc. · debt173.99 USD
AT&T Inc. · analyst target price30.37 USD
AT&T Inc. · forward pe11 multiple
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look — Source | Via News | ViaNews Market